Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer

Peer Review reports

Original Submission
26 Mar 2024	Submitted	Original manuscript
26 Jun 2024	Reviewed	Reviewer Report - Nikolaos Syrigos
3 Jul 2024	Reviewed	Reviewer Report
18 Jul 2024	Author responded	Author comments - Guo-Qing Zhang
Resubmission - Version 2
18 Jul 2024	Submitted	Manuscript version 2
Publishing
25 Jul 2024	Editorially accepted
7 Aug 2024	Article published	10.1186/s12885-024-12708-6

Back to article page